9 项
按位置名称排序#Show15202550100All per page BML-278 CAY10602 MDL-800 Piceatannol Resveratrol SirtACt SRT1720 UBCS-039 YK-3-2379 项
排序方式PositionNameCat #Show15202550100All per page类别：SIRT 激活剂抗体和阻断肽(13)检测试剂盒(4)酶(9)SIRT 激活剂(9)SIRT 抑制剂(15)
首页产品癌症研究表观遗传调节橡皮擦酶Sirtuins (SIRT)EnzymesEnzymes9 项
按位置名称排序#Show15202550100All per page Active SIRT6 (GST-人重组 Active SIRT6（His 标签）、人重组 Active SIRT7、人重组 Active Sirtuin 2 (SIRT2)、人重组人 SIRT 1 SIRT1 (193-747 aa)（GST 标签）、人重组 SIRT4 ( GST-tagged), Human recombinant SIRT5 (GST-tagged), Human recombinant SIRT7 (2-400 aa) (His-tagged), 人类重组体9 Item(s)
Sort ByPositionNameCat #Show15202550100All per page 类别：酶抗体和阻断肽(13)检测试剂盒(4)酶(9)SIRT 激活剂(9)SIRT 抑制剂(15)首页产品癌症研究表观遗传调控橡皮擦酶Sirtuins (SIRTs)检测试剂盒检测试剂盒4 项
按位置名称排序 #Show15202550100All per page SIRT2 抑制剂筛选检测试剂盒（荧光法） SIRT6 抑制剂筛选试剂盒（荧光法） Sirtuin 1（人细胞内）ELISA 试剂盒 Sirtuin 2（人细胞内）ELISA 试剂盒4 项
按位置名称排序 #Show15202550100All per页面 类别：检测试剂盒抗体和阻断肽(13)检测试剂盒(4)酶(9)SIRT 激活剂(9)SIRT 抑制剂(15)主页产品癌症研究表观遗传调节橡皮擦酶 Sirtuins (SIRT)Antibodies & Blocking PeptidesAntibodies & Blocking Peptides13 项
排序方式PositionNameCat #Show15202550100All per page SIRT1抗体 SIRT2抗体 SIRT2抗体 SIRT3抗体 SIRT3阻断肽 SIRT4抗体 SIRT4阻断肽 SIRT5抗体 SIRT5阻断肽 SIRT6抗体 SIRT7抗体 SIRT7抗体 SIRT7阻断肽13 Item(s)
Sort ByPositionNameCat #Show15202550100All per page 类别：抗体和阻断肽抗体和阻断肽(13)检测试剂盒(4)酶(9)SIRT 激活剂(9)SIRT 抑制剂(15)主页产品癌症研究表观遗传调节清除酶 Sirtuins (SIRT)Sirtuins (SIRT)抗体和阻断肽检测试剂盒酶 SIRT 激活剂SIRT 抑制剂类别： Sirtuins (SIRT) 组蛋白脱乙酰酶 (HDAC)(106)抗体和阻断肽(27)检测试剂盒(12)HDAC 酶和承印物(12) HDAC 抑制剂(55)组蛋白去甲基化酶 (HDM)(37)抗体和阻断肽(10)酶(0)HDM 抑制剂(27)缺氧诱导因子 (HIF)(3)蛋白酪氨酸磷酸酶 (PTP)(22)抗体( 3)酶(6)PTP 抑制剂(13)Sirtuins (SIRT)(50)抗体和阻断肽(13)检测试剂盒(4)酶(9)SIRT 激活剂(9)SIRT 抑制剂(15)泛素特异性蛋白酶(31) )抗体(19)DUB（去泛素化酶）和相关抑制剂(8)酶(4)首页产品癌症研究表观遗传调节清除酶蛋白酪氨酸磷酸酶 (PTP)PTP 抑制剂PTP 抑制剂13 项
排序方式PositionNameCat #Show15202550100All per page bpV (phen) bpV(pic) Calyculin A EZBlock™ 磷酸酶抑制剂混合物 I (50X) EZBlock™ 磷酸酶抑制剂混合物 II EZBlock™ 磷酸酶抑制剂混合物 III EZBlock™ 磷酸酶抑制剂混合物 IV IQ-1 Nodularin 冈田酸，冈田酸铵盐，冈田酸钾盐、钠盐13 项
按位置名称排序 #Show15202550100All per page Categories: PTP Inhibitors Antibodies( 3)酶类(6)PTP抑制剂(13)主页产品癌症研究表观遗传调控橡皮擦酶蛋白酪氨酸磷酸酶 (PTP)酶类酶类6 项
按位置名称排序 #Show15202550100All per page Human Recombinant DUSP3人类重组 PP2C alpha 人类重组 PPM1G 人类重组 PPP1CA 人类重组 PTP1B 人类重组 SHP-16 项
按位置名称排序 #Show15202550100All per page 类别：酶类抗体(3)酶类(6)PTP 抑制剂(13)首页产品癌症研究表观遗传调控橡皮擦酶蛋白酪氨酸磷酸酶 (PTP)抗体3 项
按位置名称排序 #Show15202550100All per page PTP1B Antibody PTP1B抗体 PTP1B 抗体（克隆 107AT531）3 项
按位置名称排序 #Show15202550100All per page Categories: Antibodies Antibodies(3 )酶(6)PTP 抑制剂(13)主页产品癌症研究表观遗传调控清除酶蛋白酪氨酸磷酸酶 (PTP) 蛋白酪氨酸磷酸酶 (PTP) 抗体酶 PTP 抑制剂类别： 蛋白酪氨酸磷酸酶 (PTP) 组蛋白脱乙酰酶 (HDAC)(106)抗体和阻断肽(27)检测试剂盒(12) )HDAC 酶和底物(12 )HDAC 抑制剂(55)组蛋白去甲基化酶 (HDM)(37)抗体和阻断肽(10)酶(0)HDM 抑制剂(27)缺氧诱导因子 (HIF)(3)蛋白酪氨酸磷酸酶 (PTP)(22)抗体(3)酶(6)PTP 抑制剂(13)去乙酰化酶 (SIRT)(50)抗体和阻断肽(13)检测试剂盒(4)酶(9)SIRT 激活剂(9)SIRT 抑制剂(15)泛素特异性蛋白酶( 31)抗体(19)DUB（去泛素化酶）和相关抑制剂(8)酶(4)主页产品癌症研究表观遗传调节橡皮擦酶低氧诱导因子 (HIFs)低氧诱导因子 (HIFs)3 项
排序方式PositionNameCat #Show15202550100All per page2,4-吡啶二甲酸 DMOG PX 12
3 项
按位置名称排序 #Show15202550100All per page类别： 缺氧诱导因子 (HIF) 组蛋白去乙酰化酶 (HDAC)(106)抗体和阻断肽(27)检测试剂盒(12)HDAC 酶和底物(12)HDAC 抑制剂(55)组蛋白去甲基化酶 (HDM)(37)抗体& 阻断肽(10)酶(0)HDM 抑制剂(27)缺氧诱导因子 (HIF)(3)蛋白酪氨酸磷酸酶 (PTP)(22)抗体(3)酶(6)PTP 抑制剂(13)Sirtuins (SIRT) )(50)抗体和阻断肽(13)检测试剂盒(4)酶(9)SIRT 激活剂(9)SIRT 抑制剂(15)泛素特异性蛋白酶(31)抗体(19)DUB（去泛素化酶）和相关抑制剂( 8)E酶(4)- Y-27632 is a novel and specific Rho-associated coiled-coil forming protein kinase (ROCK) inhibitor. Narumiya, S., et al. \"Use and properties of ROCK-specific inhibitor Y-27632.\" Methods Enzymol. 325: 273-284 (2000).
- This research compound is the dihydrochloride salt form of Y-27632. We also plan to offer the free base form; please see Y-27632, Free Base, Cat. No. Y-5399.
- Y-27632 inhibited ROCK-I (Ki = 0.22 µM) and ROCK-II (Ki = 0.30 µM) by competing with ATP for its binding to the kinase. Ishizaki, T., et al. \"Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.\" Mol. Pharmacol. 57: 976-983 (2000).
- Y-27632 selectively inhibited Ca2+ sensitization of smooth muscle and blocked its contraction, prevented Rho-induced, p160ROCK-mediated formation of stress fibers in cultured cells, and dramatically lowered hypertension in several hypertensive rat models. Uehata, M., et al. \"Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.\" Nature 389: 990-994 (1997).
- Y-27632 inhibited cell transformation mediated by RhoA and its guanine-nucleotide exchange factor (GEF). Sahai, E., et al. \"Transformation mediated by RhoA requires activity of ROCK kinases.\" Curr. Biol. 9: 136-145 (1999).
- Y-27632 inhibited both Rho-mediated activation of actomyosin and invasive activity of rat MM1 hepatoma cells. Continuous delivery of Y-27632 largely prevented the dissemination of MM1 cells implanted into the peritoneal cavity of syngeneic rats. Itoh, K., et al. \"An essential part for Rho-associated kinase in the transcellular invasion of tumor cells.\" Nat. Med. 5: 221-225 (1999).
- Y-27632 blocked chemotactic peptide-induced development of cell polarity and locomotion, and inhibited myosin light chain phosphorylation with similar potency (ED50 = 0.5-1.1 µM). Niggli, V. \"Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration.\" FEBS Lett. 445: 69-72 (1999).
- Y-27632 had antinociceptive properties, possibly by inhibition of Rho-kinase. Buyukafsar, K., et al. \"Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice.\" Eur. J. Pharmacol. 541: 49-52 (2006).
- Y-27632 blocked the development of ischemia/reperfusion-induced acute renal failure, possibly by inhibiting myeloperoxidase activity in an early phase after reperfusion. Teraishi, K., et al. \"Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion-induced acute renal failure in rats.\" Eur. J. Pharmacol. 505: 205-211 (2004).
- Y-27632 prevented intrahepatic metastasis of human hepatocellular carcinoma. Takamura, M., et al. \"Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632.\" Hepatology 33: 577-581 (2001).
- Y-27632 inhibited both of lysophosphatidic acid (LPA)- and fibronectin (FN)-induced migration and morphological change of rat ascites hepatoma (MM1) cells. It impaired LPA- and FN-evoked formation of focal adhesions and actin bundles and suppressed LPA- and FN-induced tyrosine phosphorylation of focal adhesion kinase and paxillin in MM1 cells. Imamura, F., et al. \"Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase.\" Jpn. J. Cancer Res. 91: 811-816 (2000).
- This Y-27632 product is the dihydrochloride salt, whose CAS number is given above. The CAS number of the free base form is 146986-50-7.
- Related CAS number: 331752-47-7 for Y-27632 diHCl salt monohydrate.
- A CAS number previously assigned to Y-27632 diHCl salt monohydrate, namely 203911-23-3, has been deleted by CAS and is no longer in use, and a CAS number previously assigned to Y-27632, Free Base, namely 742043-06-7, has also been deleted by CAS and is also no longer in use.
- As of October 2013, many other vendors (Adipogen, Affix, AG Scientific, BioVision, Calbiochem/EMD, Cellagen, Enzo, MyBioSource, Reagents Direct, Santa Cruz, VDM Biochemicals, etc.) are incorrectly using CAS number 146986-50-7 for the diHCl or diHCl monohydrate salt forms of Y-27632. Chemical Abstracts Service has assigned the CAS number 146986-50-7 to the free base form only.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
